NextFin News - Oura Health, the maker of the smart ring that turned sleep and recovery tracking into a mass-market category, is seeking to raise up to $3 billion in an initial public offering, people familiar with the matter said, a move that would make it the largest consumer-wearables listing since Peloton's 2019 debut. The Finnish-American company has been working with Goldman Sachs, Morgan Stanley, JPMorgan Chase, Allen & Co. and Jefferies on a deal targeting a listing later in 2026, after it confidentially filed a draft prospectus with the Securities and Exchange Commission in May. The question for investors is not whether Oura has grown - it has, rapidly. It is whether public markets will pay a software-like multiple for a business that still sells titanium hardware for $349 a pop.
The Deal, the Numbers and the Window
Oura's IPO push arrives at a moment when the door to public markets has swung open wider than at any time since the pandemic. SpaceX's June listing - the largest IPO in history, raising roughly $75 billion and closing its first day near a $2.2 trillion market value - did more than make its founder a trillionaire; it signaled that investors are willing to absorb enormous, long-awaited technology offerings again. Behind SpaceX, a queue of household-name private companies has formed: Strava filed confidentially in January at a $2.2 billion valuation, and OpenAI and Anthropic are reportedly lining up their own submissions.
Against that backdrop, Oura's numbers are designed to persuade. The company says it is on track to surpass five million paid members this year, a fourfold increase over the past two fiscal years, and that revenue has risen more than fourfold over the same period. It posted roughly $500 million in revenue in 2024, was on pace for about $1 billion in 2025, and CEO Tom Hale has projected sales of $1.5 billion to $2 billion in 2026. More than 5.5 million rings had been sold as of September 2025, up from 2.5 million in mid-2024.
Yet the valuation math is unforgiving. Oura's last private round, in October 2025, put the company at about $11 billion - roughly double the $5 billion mark from its 2024 round. A $3 billion primary raise against that backdrop would be a substantial equity check at a time when hardware-plus-subscription multiples remain compressed across the sector. Peloton, the closest analog for a consumer hardware brand built on recurring engagement, went public at an $8.1 billion valuation in 2019 before its market value later collapsed by more than 90 percent. Fitbit's 2015 debut valued it at roughly $4.1 billion. Oura is betting it is not a hardware company that happens to charge subscriptions, but a health-data platform that happens to ship rings.
What Oura Is Actually Selling
The bull case rests on a single proposition: that the ring is a low-friction entry point into a recurring health relationship, not the product itself. Unlike a smartwatch, which demands daily charging and a glowing screen, the ring is inert titanium that tracks heart-rate variability, body temperature, sleep stages, activity, stress and cardiovascular load - and increasingly, women's health and menopause. The $5.99 monthly membership, or $69.99 annually, unlocks the analytics, and the ring itself retails from $349 to $499.
That structure matters for valuation. Pure hardware companies trade on unit growth and gross margin; software and subscription businesses trade on retention and lifetime value. If Oura's revenue mix keeps shifting toward the membership, the market could justify a premium to a gadget maker. But the hardware is not incidental - it is the tollbooth. Every ring sold is a customer-acquisition event, and every ring that sits in a drawer is a churned subscription.
The company has been careful to frame the membership as the engine, not an add-on. In an interview, CEO Tom Hale defended the required fee as the funding source for the science behind the product.
Oura's membership model is what powers ongoing innovation, and we see strong evidence that members continue to find meaningful value month over month with a better than best-in-class retention rate.
The company says more than 80 percent of members renew after the first year, and Hale has noted that about 75 percent of members open the app at least five times a week. Explaining the reinvestment loop, he said: "We use those funds to invest in science, new capabilities or being accurate. That results in better retention, which allows us to invest more."
The pitch - that the ring is "designed to paint a truly holistic picture of your health" - asks investors to underwrite the software multiple while the hardware keeps the door open. It is a familiar argument in wearables. What makes it harder this time is that the room is no longer empty.
The Category Is Real, but the Rivals Are Arriving
Oura invented the modern smart-ring category and still leads it, but the moat is being tested. Samsung introduced the Galaxy Ring in 2024, bringing a consumer-electronics giant's distribution and brand into a segment Oura once owned alone. Apple, the dominant force in wearables through the Apple Watch, is developing a broader range of AI-powered wearables that could include a ring of its own. Whoop, valued at $10.1 billion after a $575 million funding round closed in March 2026, has signaled public ambitions with a hiring push of more than 600 roles.
The competitive pressure cuts two ways. On one hand, Samsung and Apple validate the category - they are unlikely to spend on a form factor with no future. On the other, they bring pricing power, bundling and ecosystem lock-in that a standalone ring maker cannot match. Oura's answer has been to move upmarket and outward: the Ring 4 Ceramic launched in October 2025, and acquisitions of Proxy, Sparta Science and Veri extended the company into digital identity, athletic performance and metabolic health. In March 2026 it also added Doublepoint, a Finnish firm focused on hand-motion AI and biometrics. The strategy is to become harder to replicate on the software side before the hardware becomes a commodity.
There is also a regulatory dimension worth watching. Last fall, the company received authorization from the Food and Drug Administration to study a feature to detect signs of high blood pressure. If Oura can move from wellness claims into clinically validated monitoring, it widens the gap between itself and consumer-electronics rivals - and opens reimbursement and employer-health channels that a fashion-adjacent gadget cannot reach. That is the long-game version of the thesis, and it is the one that would most clearly separate a platform from a product.
The IPO Window Is Open - but Windows Close
Timing is the quiet variable in every IPO, and Oura's is no exception. The 2026 pipeline has been the strongest in years, with US issuance at a record high, but that very strength carries a warning. A Goldman Sachs discussion recorded in July framed the question bluntly: is the surge a sign of late-cycle excess, and can the market absorb so much new supply? History suggests that when a flood of marquee names lists in a narrow window, the weaker debuts get punished first when sentiment turns.
Oura's own sequencing is telling. It filed confidentially in May - the safe, private way to test the regulatory waters - but the reported push to raise up to $3 billion and list later this year suggests management believes the window will stay open through 2026. The SpaceX debut helps: it proved that investors will show up for large, quality technology offerings. But SpaceX is a monopoly-adjacent aerospace and satellite business with government contracts and a decade-long lead; Oura is a consumer brand whose next two quarters will be read for signs of holiday demand, retention and margin. A weak SpaceX follow-through, or a soft consumer-spending print, could narrow the path.
There is also a geographic subtext. Oura was founded in Finland and built around Nordic sleep research, but it transitioned to a US-based parent, Oura Inc., headquartered in San Francisco, to access American venture capital. Its decision to prepare for a US listing rather than a European one reflects a wider pattern among high-growth European tech firms seeking deeper capital markets and greater investor familiarity with consumer technology. For Europe's start-up ecosystem, the listing is another data point in the debate over whether the continent is losing its strongest technology companies to Wall Street.
The Counter-Thesis: Peloton Without the Pandemic Tailwind
The strongest argument against Oura's valuation is the simplest: consumer hardware companies with subscription attachments have a poor public-market record, and the conditions that made Oura a household name are not repeatable. Peloton went public at $8.1 billion on pandemic-driven demand that proved transient; its shares later fell more than 90 percent. Fitbit, once the category leader, was acquired by Google at a fraction of its IPO-era promise. Whoop and Strava are still private, which means there is no public comparable to anchor Oura's multiple - investors will be pricing blind.
There is also the question of what the $3 billion is for. A primary raise of that size implies ambitious plans - international expansion, AI development, perhaps acquisitions - but it also means meaningful dilution for existing shareholders, including Fidelity, ICONIQ, Dexcom, Forerunner Ventures and Square. If the market assigns Oura a hardware-like multiple of, say, four to six times sales on $1.5 billion to $2 billion of revenue, the implied value lands well below the $11 billion private mark. The company would then face the unenviable choice of downsizing the deal or accepting a down round in public.
The answer to that thesis is retention and mix. Oura's reported 80 percent first-year renewal rate, fourfold member growth and a revenue base that has quadrupled in two years are not Peloton-like in trajectory - they look more like a platform finding product-market fit than a fad peaking. The company has also diversified beyond sleep into broader preventative health, which widens the addressable market beyond the wellness-obsessed early adopters who bought the first rings. If membership revenue keeps compounding faster than hardware unit sales, the software-multiple argument holds.
But the burden of proof sits with the company, not the skeptics. A smart ring is a one-time purchase with a recurring fee attached; a smartwatch is a one-time purchase with an optional fee attached. The difference matters less when Apple and Samsung can bundle their services into existing ecosystems at a price a standalone player cannot match. Oura's defense is data depth and clinical credibility - years of sleep and recovery research that rivals cannot instantly replicate. Its vulnerability is that it is one product cycle away from being outflanked.
What to Watch and the Road Ahead
The short-term read is straightforward: Oura's debut will be a barometer for consumer-technology appetite in the second half of 2026. A strong pricing near the $11 billion private valuation would clear the way for Whoop, Strava and other fitness-adjacent names waiting in the wings. A muted one would send them back to private markets and put pressure on Oura's own guidance.
Medium term, the stock will be judged on the metrics that separate platforms from gadgets: paid-member growth, renewal rates, and the revenue split between rings and subscriptions. The prospectus, when it becomes public, will offer the first detailed look at gross margins on the $350 hardware versus the $5.99 monthly membership, and at the geographic split of sales. That is where the valuation will be won or lost.
Long term, the structural question is whether a standalone wearable can survive the arrival of the platform giants. Oura's best defense is data depth and clinical credibility. Its vulnerability is that it is one product cycle away from being outflanked.
Base case: Oura lists later in 2026 at a valuation modestly below its $11 billion private mark, with the market rewarding member growth but discounting hardware exposure. Upside case: a strong consumer-spending backdrop and a clean retention print push the listing above $11 billion, reopening the wearables pipeline. Downside case: a soft IPO window or weak guidance forces a downsized deal below $8 billion, reviving the Peloton comparison.
The falsifying signal is specific: if Oura's paid-member growth slows materially below the fourfold two-year pace ahead of pricing, or if first-year renewal falls below the reported 80 percent, the platform thesis breaks and the hardware multiple applies. Watch the prospectus for the membership-revenue share - if hardware stays above roughly two-thirds of total revenue, the software story loses its footing.
Oura is not selling rings to public investors; it is selling the idea that a piece of titanium can be valued like a software company - and the market is about to decide which one it really is.
Explore more exclusive insights at nextfin.ai.
